This study investigated the possible mechanisms underlying the paradoxical caspofungin activity in vivo in preclinical aspergillosis. We evaluated the activity of escalating doses of caspofungin in vivo in different preclinical models of invasive aspergillosis, including mice deficient for selected innate immune receptors. The therapeutic efficacy of caspofungin in experimental invasive aspergillosis was strictly dose dependent, being observed at doses of 0.1 and 1 mg/kg of body weight depending on the experimental models. Paradoxical increase in pulmonary fungal burden as well as inflammatory pathology was observed at the highest dose of caspofungin (5 mg/kg), occurred independently of the so-called Eagle effect and susceptibility to caspofungin in vitro, and was contingent upon the presence of TLR2, Dectin-1, and TLR9. Increased expression of Dectin-1 and TLR9 were observed upon exposure to caspofungin in vitro and in vivo. Together, these findings suggest that the net activity of caspofungin in vivo is orchestrated by the activation, directly or indirectly, of multiple innate immune receptors.
Invasive mold infections are major causes of morbidity and mortality among severely immunocompromised individuals (24,34). Aspergillus fumigatus is currently the most important airborne fungal pathogen and causes different kinds of disease, ranging from allergies to life-threatening infections depending on the immune status of the host (35). The risk of invasive Aspergillus infection is particularly high for patients with persistent neutropenia, graft-versus-host disease (especially with concomitant steroid therapy), and certain types of hematopoietic transplantation (24,26,34).The echinocandins are the newest addition to the arsenal against fungal infections. They demonstrate similar in vitro and in vivo activity against Aspergillus spp., but only caspofungin (CAS) is approved for treatment of patients who are intolerant of or refractory to other therapies (27,38). CAS has been evaluated in the salvage and primary therapy of invasive aspergillosis, and combination regimens incorporating an echinocandin were promising in the treatment of aspergillosis (11). Echinocandins exhibit a unique, fungus-specific mechanism of action by targeting 1,3--D-glucan synthase (14,17,19), thereby inhibiting the biosynthesis of 1,3--D-glucan, an important component of the fungal cell wall. In addition to having a structural role, -glucan, as a fungal pathogen-associated molecular pattern (PAMP), exhibits potent immunostimulatory properties mediated by pattern recognition receptors (PRRs), such as Toll-like receptors (TLRs) and C-type lectin receptors (CLRs), which are expressed on host cells. Dectin-1 is the main PRR that recognizes -glucans. Following binding, it induces the activation of phagocytic and proinflammatory responses (13).Studies with Candida albicans and Saccharomyces cerevisiae have revealed an echinocandin-susceptible genetic network that conceals -glucan from the immune system, thus limiting an effective host respons...